Successful treatment of class V+IV lupus nephritis with multitarget therapy.
about
Treatment for lupus nephritisLupus Nephritis in Asia: Clinical Features and ManagementNanosized contrast agents to noninvasively detect kidney inflammation by magnetic resonance imagingLong-term data on tacrolimus treatment in lupus nephritis.Successful treatment of severe crescentic lupus nephritis by multi-target therapy using tacrolimus and mycophenolate mofetilSex Differences in the Blood Concentration of Tacrolimus in Systemic Lupus Erythematosus and Rheumatoid Arthritis Patients with CYP3A5*3/*3Mycophenolate mofetil: effects on cellular immune subsets, infectious complications, and antimicrobial activityCurrent status of lupus nephritis.Recent clinical trials in lupus nephritis.Efficacy and cytokine modulating effects of tacrolimus in systemic lupus erythematosus: a review.Cyclophosphamide and lupus nephritis: when, how, for how long?Comparison of renal response parameters for juvenile membranous plus proliferative lupus nephritis versus isolated proliferative lupus nephritis: a cross-sectional analysis of the CARRA Registry.Renal involvement in autoimmune connective tissue diseases.Calcineurin inhibitors may be a reasonable alternative to cyclophosphamide in the induction treatment of active lupus nephritis: A systematic review and meta-analysis.Understanding lupus nephritis: diagnosis, management, and treatment options.American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritisRole of serum anti-C1q antibodies as a biomarker for nephritis activity in pediatric and adolescent Egyptian female patients with SLESuccess using tacrolimus in patients with proliferative and membranous lupus nephritis and refractory proteinuria.Oral cyclophosphamide for lupus glomerulonephritis: an underused therapeutic option.TAC-TIC use of tacrolimus-based regimens in lupus nephritis.Review: Lupus nephritis: pathologic features, epidemiology and a guide to therapeutic decisions.Major lupus organ involvement: severe lupus nephritis.Treatment of proliferative lupus nephritis: a slowly changing landscape.Clinicopathological insights into lupus glomerulonephritis in Japanese and Asians.Balancing efficacy and toxicity of novel therapies in systemic lupus erythematosus.Recent progress in the treatment of lupus nephritis.Pediatric lupus nephritis: more options, more chances?Overview of lupus nephritis management guidelines and perspective from Asia.Top 10 developments in lupus nephritis.Treatment of young patients with lupus nephritis using calcineurin inhibitors.Overview of lupus nephritis management guidelines and perspective from Asia.Treatment of lupus nephritis: practical issues in Asian countries.Treatment of severe lupus nephritis: the new horizon.The multifaceted aspects of refractory lupus nephritis.Mycophenolate mofetil for lupus nephritis: an update.Post-marketing surveillance study of the long-term use of mizoribine for the treatment of lupus nephritis: 2-Year results.Towards new avenues in the management of lupus glomerulonephritis.The safety of pharmacological treatment options for lupus nephritis.Clinico-pathological features of repeat renal biopsies in patients with lupus nephritis at Groote Schuur Hospital, Cape Town.Treatment of pediatric-onset lupus nephritis: a proposal of optimal therapy.
P2860
Q24202572-942F7F15-114F-448B-A126-D24FA89DEA48Q26740487-15E18F5B-1374-411D-BF67-CA616830587AQ26864381-883A613B-ED9E-4BC3-8392-50A75CCBC16EQ30835209-A37B5564-77EA-41D7-83ED-242266E9FA6BQ33628340-078B25EB-0F0A-4E0A-8EA9-B3F4D6B28DE9Q33710324-65A913D9-8D8F-4E35-BF5B-F0862BC3EFEAQ33781206-6368C459-ABF0-474F-BA1E-0E873CAEB90EQ33882751-1B411F53-A783-470B-97BA-C8B857457EE1Q33924437-A8A6B629-31CC-440A-8186-1F45BFEEE63DQ33960223-8A8DE722-570C-4598-93F8-0EF5DA7DA0A0Q34095231-8DBEEDF1-B471-48A1-8E4F-DEA84966A694Q34324887-0F17667F-5C8B-40F3-B163-93EB1A6C1A68Q34654954-99E8F71D-B675-470D-881A-6B8D1496A573Q35187502-05E53608-36B1-457C-9402-D76FA72680A4Q36008840-0712EF5E-72B5-4D10-8878-6B83BA06E4E1Q36221407-CB1C25F2-F18F-4880-8E31-5F419DD61F42Q36634902-5C5DDB8C-69D2-4BCE-9DF2-B4154132D38DQ37150681-FC73C736-1142-414D-987F-813007F9EB3FQ37415711-F29162F2-EEAF-41B8-836B-DA6A1E684AE5Q37587317-AC5C80AF-6AAB-4ACC-862E-D30FBE6751B4Q37678723-484C7FBB-88FA-48D1-97EE-AC18BD453A29Q37800295-872CFF56-9AE3-4EF2-B37E-9611FDB400E5Q37822658-5D3EF4B5-CD78-4CD1-958E-FBEEF73AF6A5Q37857737-5913C095-AFB0-4FDE-83C5-436FEAD05A45Q37960525-3663CE59-38E0-49B0-A37C-C43EF3CC9A39Q38010014-CDBAE30E-258A-4EAD-AB34-A2D4ECD43695Q38102946-F5FBABE2-33C6-4BDC-B571-944212BF57D7Q38123242-B34D169E-8C1D-44F0-B3BA-67C560CB00E6Q38124761-7E81B988-9CBB-4CA0-BB85-93B8BBD0DE0AQ38156915-23FCEEA5-650D-4023-91C8-32489F860A6AQ38175076-F1995926-29B9-41CA-88BA-7CDB2AAB3575Q38223302-ACBA81D7-1E9F-4573-8559-830480BEC837Q38271125-8B426295-DD76-43BA-944B-0E6A491DF4FDQ38285375-B450B129-0DC3-4CA2-8772-BDD0FEEED0C3Q38585887-443F0F3C-0815-4833-94BB-36EEB53F5337Q38672493-F70E5F9F-037F-4FD9-8B9E-AF05738C9CB5Q38686467-A547E6F7-FD8F-4945-82A0-4161CE1F4D03Q38829637-5F573FAF-9DA9-4A39-B714-8A48EC6D2A16Q38831846-F2241174-F3D2-45BA-B0BE-BF5F8DD14344Q39160729-B426128D-14A8-403B-9C5C-070591D4EAE7
P2860
Successful treatment of class V+IV lupus nephritis with multitarget therapy.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Successful treatment of class V+IV lupus nephritis with multitarget therapy.
@en
type
label
Successful treatment of class V+IV lupus nephritis with multitarget therapy.
@en
prefLabel
Successful treatment of class V+IV lupus nephritis with multitarget therapy.
@en
P2093
P2860
P356
P1476
Successful treatment of class V+IV lupus nephritis with multitarget therapy
@en
P2093
Hai-Tao Zhang
Hong-Lang Xie
Lei-Shi Li
Wei-Xin Hu
P2860
P304
P356
10.1681/ASN.2007121272
P50
P577
2008-07-02T00:00:00Z